MX2020002692A - Formulacion de resiniferatoxina. - Google Patents
Formulacion de resiniferatoxina.Info
- Publication number
- MX2020002692A MX2020002692A MX2020002692A MX2020002692A MX2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A
- Authority
- MX
- Mexico
- Prior art keywords
- rtx
- resiniferatoxin
- disclosed
- formulation
- formulations
- Prior art date
Links
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 title abstract 4
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 title abstract 3
- 229940073454 resiniferatoxin Drugs 0.000 title abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 230000005484 gravity Effects 0.000 abstract 1
- 238000007913 intrathecal administration Methods 0.000 abstract 1
- 150000002772 monosaccharides Chemical class 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556824P | 2017-09-11 | 2017-09-11 | |
| PCT/IB2018/056944 WO2019049112A1 (en) | 2017-09-11 | 2018-09-11 | RESINIFERATOXIN FORMULATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002692A true MX2020002692A (es) | 2020-10-14 |
Family
ID=63708422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002692A MX2020002692A (es) | 2017-09-11 | 2018-09-11 | Formulacion de resiniferatoxina. |
| MX2022013947A MX2022013947A (es) | 2017-09-11 | 2020-03-10 | Formulacion de resiniferatoxina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013947A MX2022013947A (es) | 2017-09-11 | 2020-03-10 | Formulacion de resiniferatoxina. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190076396A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3681472A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7358337B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200051771A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111315360B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018327301B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3074951A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020002692A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019049112A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| WO2020226370A1 (ko) | 2019-05-09 | 2020-11-12 | 주식회사 엘지화학 | 전기화학소자용 분리막 및 이를 포함하는 전기화학소자 |
| US20230143545A1 (en) * | 2020-03-30 | 2023-05-11 | Board Of Regents Of The University Of Nebraska | Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin |
| ES3004508T3 (en) * | 2020-04-15 | 2025-03-12 | Gruenenthal Gmbh | Resiniferatoxin compositions |
| WO2021257956A1 (en) * | 2020-06-19 | 2021-12-23 | Sorrento Therapeutics, Inc. | Administration of resiniferatoxin for treatment of bladder pain or bladder cancer |
| EP4291174A1 (en) * | 2021-02-11 | 2023-12-20 | Sorrento Therapeutics, Inc. | Administration of resiniferatoxin for treatment of prostate cancer |
| US20250228765A1 (en) | 2024-01-15 | 2025-07-17 | Gruenenthal Gmbh | Treating knee joint pain by injecting resiniferatoxin at ultra low doses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2187193B (en) | 1986-02-27 | 1989-11-08 | Gerald Scott | Controllably and swiftly degradable polymer compositions and films and other products made therefrom |
| US5021450A (en) | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
| US5232684A (en) | 1990-06-29 | 1993-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Labelled resiniferatoxin, compositions thereof, and methods for using the same |
| US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
| NZ540769A (en) * | 2002-12-18 | 2009-03-31 | Algorx Pharmaceuticals Inc | Administration of capsaicinoids for the treatment of pain |
| CN101119713A (zh) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | 类辣椒素凝胶制剂及其用途 |
| EP1838301B1 (de) * | 2004-12-28 | 2015-01-28 | Mestex AG | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen |
| ES2384244T3 (es) * | 2004-12-28 | 2012-07-02 | Mestex Ag | Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco |
| US9956166B2 (en) * | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| CN113490745A (zh) * | 2018-12-21 | 2021-10-08 | 索伦托药业有限公司 | 神经周施用树脂毒素治疗适应不良性疼痛 |
| WO2020154261A1 (en) * | 2019-01-22 | 2020-07-30 | Sorrento Therapeutics, Inc. | Method for treating osteoarthritis pain by administering resiniferatoxin |
-
2018
- 2018-09-11 US US16/128,053 patent/US20190076396A1/en not_active Abandoned
- 2018-09-11 EP EP18779459.9A patent/EP3681472A1/en not_active Withdrawn
- 2018-09-11 CA CA3074951A patent/CA3074951A1/en active Pending
- 2018-09-11 MX MX2020002692A patent/MX2020002692A/es unknown
- 2018-09-11 AU AU2018327301A patent/AU2018327301B2/en not_active Ceased
- 2018-09-11 WO PCT/IB2018/056944 patent/WO2019049112A1/en not_active Ceased
- 2018-09-11 CN CN201880072756.3A patent/CN111315360B/zh active Active
- 2018-09-11 JP JP2020514270A patent/JP7358337B2/ja active Active
- 2018-09-11 KR KR1020207010367A patent/KR20200051771A/ko not_active Ceased
-
2020
- 2020-03-10 MX MX2022013947A patent/MX2022013947A/es unknown
-
2022
- 2022-01-05 US US17/569,340 patent/US20220370405A1/en not_active Abandoned
- 2022-10-07 JP JP2022162509A patent/JP2022176377A/ja active Pending
-
2024
- 2024-03-29 US US18/622,139 patent/US20250000842A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200051771A (ko) | 2020-05-13 |
| US20220370405A1 (en) | 2022-11-24 |
| AU2018327301A1 (en) | 2020-04-09 |
| AU2018327301B2 (en) | 2024-08-22 |
| CN111315360B (zh) | 2025-01-17 |
| CA3074951A1 (en) | 2019-03-14 |
| MX2022013947A (es) | 2022-11-30 |
| JP2020533336A (ja) | 2020-11-19 |
| EP3681472A1 (en) | 2020-07-22 |
| JP7358337B2 (ja) | 2023-10-10 |
| WO2019049112A1 (en) | 2019-03-14 |
| US20250000842A1 (en) | 2025-01-02 |
| JP2022176377A (ja) | 2022-11-25 |
| CN111315360A (zh) | 2020-06-19 |
| US20190076396A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018327301A1 (en) | Formulation of resiniferatoxin | |
| EP4338752A3 (en) | Stable liquid pharmaceutical preparation | |
| IL272367A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SA519401317B1 (ar) | تركيبات أو مستحضرات لقاح المكورات الرئوية متعددة التكافؤ والتي تضم اتحادات البروتين مع عديد السكاريد | |
| EP4684797A3 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
| WO2019171253A8 (en) | Anti-pd-1 antibody compositions | |
| NZ731248A (en) | Cannabis extracts and methods of preparing and using same | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| MX2017009759A (es) | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
| MY197534A (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| CL2017003437A1 (es) | Formulación solida oral que contiene irinotecán y método de preparación de la misma | |
| WO2021118930A3 (en) | Anti-pd-l1 antibody formulations | |
| EP4509178A3 (en) | High purity oritavancin and method of producing same | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| PH12017502319A1 (en) | Injectable pharmaceutical formulations of lefamulin | |
| WO2019027221A3 (ko) | pH 민감성 성분의 안정화용 조성물 | |
| MX390441B (es) | Formulaciones liquidas de fosfaplatino. | |
| PH12014502323A1 (en) | Oral formulation | |
| IL290651A (en) | Novel soluble liquid compositions of saflufenacil, method of preparation and use thereof | |
| CR20200552A (es) | Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe | |
| EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола |